Germany· DE-A57-958bcd56a46cdeda
Alogliptin Heumann
A alogliptin product containing alogliptin, registered in Germany by Heumann Pharma Gmbh & Co. Generica Kg. The same ATC class is registered in 13 of our 19 countries.
Checked against EMA Article 57 (European Union) on
Informational only — not a medical device.
Where it is registered
Alogliptin is registered in 13 of 19 countries.
Countries holding a registration under ATC A10BH04 (alogliptin), each read from that country’s own register.
- This record: Germany, from EMA Article 57 (European Union)
- 6 of them publish a price we can compare per daily dose
Alogliptin · ATC A10BH04
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Polandprice
- United Kingdom
Price per daily dose
What a daily dose of alogliptin costs, country by country.
Normalised to the WHO defined daily dose (25 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Alogliptin · price per daily dose (25 mg)
USD · FX 28 Sept 2026
- IT Italy$4.54
The record
At a glance
EMA Article 57 (European Union)- Active substance
- Alogliptin
- Manufacturer
- Heumann Pharma Gmbh & Co. Generica Kg
- Country
- Germany (DE)
- ATC code
- A10BH04
- ATC class
- Alogliptin
- Defined daily dose
- 25 mg, O
- Reimbursed
- Not published by this register
- Source register
- EMA Article 57 (European Union)
- Last checked
- September 30, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
312 interactions on record for alogliptin.
Graded by severity as the source publishes them — 3 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Alogliptin · interactions on record
312 records
- 3 severe
- 269 moderate
- 40 minor
Most severe, free to view
- GatifloxacinJ01MA16severe
- SucralfateA02BX02moderate
- ThiethylperazinA04AB03moderate
- TriflupromazinA04AD06moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Alogliptin in 9 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomAlogliptin 12.5mg tabletsEnnogen Healthcare Ltd
- SpainVIPIDIA 12,5 MG COMPRIMIDOS RECUBIERTOS CON PELICULATakeda Pharma A/S
- IcelandVipidiaTakeda Pharma A/S
- ItalyVIPIDIA*28 cpr rivestite 12,5 mgTAKEDA PHARMA A/S
- Japanアログリプチン安息香酸塩帝人ファーマ
- NetherlandsVipidia 12,5 mg filmomhulde tablettenTakeda Pharma A/S
- PolandVipidiaTakeda Pharma A/S
- CanadaNESINATAKEDA CANADA INC
Authorised across Europe · EMA
The same active substance is authorised in 5 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Alogliptin Aspire Pharma, Alogliptin Torrent
- Iceland · Vipidia
- Liechtenstein · Vipidia
- Malta · Alogliptin Torrent
- Norway · Vipidia
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of EMA Article 57 (European Union). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/85a867b0-f1c1-4ce2-899f-d3fd93c4b207 GET /v1/drugs/85a867b0-f1c1-4ce2-899f-d3fd93c4b207?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"pzn": null,
"route": "Oral Use",
"source": "ema_art57_de",
"ma_number": null,
"substance": "Alogliptin",
"atc_from_source": null,
"authorisation_country": "Germany"
}See everything about alogliptin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.